Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
West High Yield Resources Ltd. Announces First Tranche Closing of Private Placement and Record Ridge Project Update
